Abril A Pérez-Arias1, R Angélica Méndez-Pérez1, Cristino Cruz1, María Fernanda Zavala-Miranda1, Juanita Romero-Diaz2, Sofía E Márquez-Macedo1, Roque A Comunidad-Bonilla1, C Carolina García-Rueda2, Juan M Mejía-Vilet3. 1. Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán, Belisario Dominguez Sección XVI, 15 Vasco de Quiroga, Tlalpan, Mexico City, Mexico. 2. Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Mexico. 3. Department of Nephrology and Mineral Metabolism, Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán, Belisario Dominguez Sección XVI, 15 Vasco de Quiroga, Tlalpan, Mexico City, Mexico. jmejiavilet@gmail.com.
Abstract
OBJECTIVES: The present study aims to assess the course of uMCP-1 and its association with response to therapy and long-term kidney function in a prospective cohort of adults who received a kidney biopsy for suspicion of active lupus nephritis (LN). METHODS: Subjects were segregated into a histologically active LN group and a histologically chronic LN group. Both groups were followed for > = 36 months and urine were collected at flare, 3, 6, and 12 months of follow-up. The association between the course of uMCP-1, response to treatment, and progression to 30% loss of the eGFR was evaluated by linear mixed models for repeated measures. RESULTS: A kidney biopsy was performed on 125 subjects. In 114, the report was consistent with histologically active LN; in 11, with histologically chronic LN. Urine MCP-1 levels were significantly higher in the active LN than in the chronic LN group. Urine MCP-1 levels correlated with the histological findings of cellular crescents, endocapillary hypercellularity, interstitial inflammation, glomerular sclerosis, interstitial fibrosis, and tubular atrophy. The mean estimates of uMCP-1 at flare were higher in the non-response group than in the complete response group, and decreased in the complete/partial response groups by the third month, while they remained elevated in the non-response group. The mean estimates for uMCP-1 were higher at LN flare and remained elevated in patients who progressed to loss of 30% of the eGFR, while they decreased in patients with stable kidney function. CONCLUSION: The first-year course of uMCP-1 is associated with response to therapy and kidney survival in LN. Key Points •Urine MCP-1 levels differentiate histologically-active lupus nephritis from histologically-chronic lupus nephritis •Urine MCP-1 levels decrease by 3 months of therapy in subjects with a favorable response whose kidney function remains stable long-term •Urine MCP-1 levels remain elevated during the first year of therapy in subjects the will later lose kidney function.
OBJECTIVES: The present study aims to assess the course of uMCP-1 and its association with response to therapy and long-term kidney function in a prospective cohort of adults who received a kidney biopsy for suspicion of active lupus nephritis (LN). METHODS: Subjects were segregated into a histologically active LN group and a histologically chronic LN group. Both groups were followed for > = 36 months and urine were collected at flare, 3, 6, and 12 months of follow-up. The association between the course of uMCP-1, response to treatment, and progression to 30% loss of the eGFR was evaluated by linear mixed models for repeated measures. RESULTS: A kidney biopsy was performed on 125 subjects. In 114, the report was consistent with histologically active LN; in 11, with histologically chronic LN. Urine MCP-1 levels were significantly higher in the active LN than in the chronic LN group. Urine MCP-1 levels correlated with the histological findings of cellular crescents, endocapillary hypercellularity, interstitial inflammation, glomerular sclerosis, interstitial fibrosis, and tubular atrophy. The mean estimates of uMCP-1 at flare were higher in the non-response group than in the complete response group, and decreased in the complete/partial response groups by the third month, while they remained elevated in the non-response group. The mean estimates for uMCP-1 were higher at LN flare and remained elevated in patients who progressed to loss of 30% of the eGFR, while they decreased in patients with stable kidney function. CONCLUSION: The first-year course of uMCP-1 is associated with response to therapy and kidney survival in LN. Key Points •Urine MCP-1 levels differentiate histologically-active lupus nephritis from histologically-chronic lupus nephritis •Urine MCP-1 levels decrease by 3 months of therapy in subjects with a favorable response whose kidney function remains stable long-term •Urine MCP-1 levels remain elevated during the first year of therapy in subjects the will later lose kidney function.
Authors: Juan M Mejia-Vilet; Xiaolan L Zhang; Cristino Cruz; Mayra L Cano-Verduzco; John P Shapiro; Haikady N Nagaraja; Luis E Morales-Buenrostro; Brad H Rovin Journal: J Am Soc Nephrol Date: 2020-04-16 Impact factor: 10.121
Authors: Brad H Rovin; Huijuan Song; Dan J Birmingham; Lee A Hebert; Chack Yung Yu; Haikady N Nagaraja Journal: J Am Soc Nephrol Date: 2004-12-15 Impact factor: 10.121
Authors: Desmond Y H Yap; Colin S O Tang; Maggie K M Ma; Man Fai Lam; Tak Mao Chan Journal: Nephrol Dial Transplant Date: 2012-04-20 Impact factor: 5.992
Authors: Hermine I Brunner; Michael R Bennett; Rina Mina; Michiko Suzuki; Michelle Petri; Adnan N Kiani; Joshua Pendl; David Witte; Jun Ying; Brad H Rovin; Prasad Devarajan Journal: Arthritis Rheum Date: 2012-08
Authors: T Wada; H Yokoyama; S B Su; N Mukaida; M Iwano; K Dohi; Y Takahashi; T Sasaki; K Furuichi; C Segawa; Y Hisada; S Ohta; K Takasawa; K Kobayashi; K Matsushima Journal: Kidney Int Date: 1996-03 Impact factor: 10.612
Authors: Yiann E Chen; Stephen M Korbet; Robert S Katz; Melvin M Schwartz; Edmund J Lewis Journal: Clin J Am Soc Nephrol Date: 2007-11-14 Impact factor: 8.237